

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

ANNOUNCEMENT POSITIVE PROFIT ALERT

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders and potential investors of the Company that, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the Company’s management, the Group is expected to record an unaudited consolidated net profit of the Group of not less than RMB115 million and an unaudited consolidated net profit attributable to the owners of the parent of not less than RMB105 million for the six months ended 30 June 2021 (the “**Interim Period 2021**”) as compared to an unaudited consolidated net loss of the Group of approximately RMB702.8 million and an unaudited consolidated net loss attributable to the owners of the parent of approximately RMB640.3 million for the six months ended 30 June 2020.

The expected turnaround from net loss to net profit of the Group for the Interim Period 2021 are primarily attributed to the following:

1. The significant increase in revenue of our medical business, which was due to a big rebound in the demand on our IVD products resulted from the general recovery of medical industry in the PRC.
2. An absence of impairment loss on goodwill in all non wholly-owned subsidiaries of the Company, which was due to the full resumption of their operations resulted from the release of regional lockdowns measures in the PRC.

The Group is still in the process of finalizing its unaudited consolidated results for the Interim Period 2021. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited management accounts for the Interim Period 2021 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board and review by the external auditors of the Company. Details of the unaudited financial performance of the Group will be contained in the interim results announcement of the Group for the Interim Period 2021, which is expected to be published on 30 August 2021.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

20 August 2021

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Ms. Wang Hong, Ms. Liao Changxiang and Mr. Li Bin; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.